CSS Responds: Sources of Regional Variation in Medicare Part D Drug Spending, The New England Journal of Medicine

A recent NEJM study indicated nearly a two-fold difference between brand name drug use in low cost versus high cost regions (Donohue, et al, NEJM 366; 6). The Donohue study calculated that if all Medicare regions used brand name drugs in a manner similar to the lowest cost regions, the Medicare program could save approximately $4.5 billion in drug spend (~$11 million per Part D plan).

The Problem: The problem, as Donohue notes, is that using typical formulary tactics to eliminate brand drug use “…would deprive some patients of needed treatment options”.

The Solution: CSS’s iDeal Therapy is a focused medication management program that uses patients’ clinical features to identify and eliminate inappropriate brand drug use.

Let us know what you think?

AUTHOR

James Notaro, RPh, PhD

More Recent Posts

  • Patient Acceptance of Pharmacist Run Transition of Care Service

    A recent article in Innovations in Pharmacy, describes a unique pharmacy based transition of care service. Kowalski et. al. describe … Continued

  • Are ACOs Prepared to Managed Medication Quality and Cost

    BACKGROUND Recentlt Wilks et. al published Optimization of Medication Use at Accountable Care Organizations.The authors studied accountable care organizations’ (ACO) … Continued

  • Integrating pharmacists into the patient centered medical home

    Recently Intermountain Healthcare (IH) reported on effort to integrate pharmacists in their patient centered medical home (PCMH).  IH is an … Continued

  • Request a Demo

    This is a basic introduction to MTMPath, our web-based MTM solution. We have a number of different modules to suit specific MTM needs. We will contact you to schedule an informational meeting after your introduction to MTMPathTM through our medication management software demo.